Smallpox Clinical Trial
Official title:
Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults.
Primary Objective:
To estimate the smallpox vaccination take rate in healthy young adults not previously
vaccinated with a smallpox vaccine.
Secondary Objectives:
To describe antibody response to vaccination and evaluate the take for each subject at
various timepoints for each batch and pooled batches and to evaluate local signs, symptoms,
and overall safety in healthy young adults not previously vaccinated with a smallpox
vaccine.
| Status | Completed |
| Enrollment | 230 |
| Est. completion date | January 2007 |
| Est. primary completion date | December 2006 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 25 Years |
| Eligibility |
Inclusion Criteria: - Aged 18 to 25 years on the day of screening - Informed consent form signed - Able to attend all scheduled visits and to comply with all trial procedures - For a woman, inability to bear a child or negative serum pregnancy test performed at screening (Visit 01) - Subject entitled to national social security - Subject registered in the French file of healthy volunteers in clinical trials - For a woman of child-bearing potential: use of an effective method of contraception (hormonal or barrier method) from at least 3 months prior to screening to 3 months following trial vaccination - For a woman, inability to bear a child or negative urine pregnancy test. Exclusion Criteria: - Previous smallpox vaccination confirmed by vaccination record or typical scar - Participation in another trial in the 3 months before or during the trial period - Acute intercurrent or chronic illness during the trial - Breast-feeding - Allergy or sensitivity to any known components of vaccinia immune globulin or previous reaction to immunoglobulins or trial vaccine - Congenital or acquired immunodeficiency or immunosuppressive therapy or any treatment including corticosteroids - Treatment with antiviral drugs within 1 month before vaccination - History of organ or bone marrow transplant or skin disorders - Personal or family history of autoimmune disease or cardiac disease, including cardiac risk factors - History or current central nervous system disease - Ongoing acute infectious disease - Blood or blood-derived products received in the past 6 months - Any vaccination with a live-attenuated vaccine within the 60 days or other vaccines within 40 days preceding the trial vaccination - Vaccination planned in the 8 weeks following the trial vaccination - Planned or foreseeable close contact after vaccination with infants less than 12 months, or with immuno-suppressed persons, pregnant and/or lactating woman, or practice of contact or water sports after vaccination before the crust separates - Skin wound near the vaccination site - Apparent lack of personal hygiene - Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent - HIV, hepatitis B or hepatitis C seropositivity (screening tests) - Abnormal lab values for hematological parameters or cardiac enzyme (screening tests) - Feverish illness (oral temperature >=37.5°C, rectal equivalent temperature >=38.0°C) on the day of vaccination. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Sanofi |
France,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05976100 -
Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years
|
Phase 1 | |
| Completed |
NCT01540929 -
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
|
||
| Completed |
NCT00189969 -
Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects
|
Phase 1 | |
| Terminated |
NCT00053508 -
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
|
Phase 2 | |
| Completed |
NCT01317238 -
Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers
|
Phase 3 | |
| Completed |
NCT01056770 -
Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers
|
Phase 3 | |
| Withdrawn |
NCT00389103 -
Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)
|
Phase 1 | |
| Terminated |
NCT00282581 -
Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive
|
Phase 1 | |
| Completed |
NCT00998543 -
A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)
|
Phase 2 | |
| Completed |
NCT00133575 -
ACAM 3000 MVA at Harvard Medical School
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00103584 -
Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers
|
Phase 1/Phase 2 | |
| Completed |
NCT00050505 -
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
|
Phase 2 | |
| Completed |
NCT05846243 -
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
|
Phase 2/Phase 3 | |
| Completed |
NCT05935917 -
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00082446 -
Combination Study With MVA BN and Dryvax
|
Phase 1 | |
| Completed |
NCT00038987 -
Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
|
Phase 1/Phase 2 | |
| Completed |
NCT05762523 -
Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years
|
Phase 1 | |
| Completed |
NCT04971109 -
Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day
|
Phase 3 | |
| Completed |
NCT00646152 -
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
|
Phase 1 | |
| Completed |
NCT01668537 -
A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects
|
Phase 2 |